Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04167163 · ClinicalTrials.gov registry record · Phase 4
Abaloparatide Before Total Knee Arthroplasty
A Phase 4 study of Osteoporosis and Arthroplasties, Knee Replacement, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT04167163 is a Phase 4 study of Osteoporosis and Arthroplasties, Knee Replacement that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 58 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04167163, a Phase 4 study of Osteoporosis and Arthroplasties, Knee Replacement, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigator hypothesizes that treating osteoporotic patients with abaloparatide prior to and after total knee arthroplasty will significantly reduce the amount of bone loss.
Conditions Studied
Interventions
- DRUG Abaloparatide
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2020-01-10 |
| Est. Completion | 2025-04-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04167163
The ClinicalTrials.gov registry entry for NCT04167163 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (96% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Osteoporosis appearing as the primary indexed condition, and to 1 intervention - of which Abaloparatide is the first listed.
NCT04167163 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04167163 about?
NCT04167163 is a clinical study titled "Abaloparatide Before Total Knee Arthroplasty". The investigator hypothesizes that treating osteoporotic patients with abaloparatide prior to and after total knee arthroplasty will significantly reduce the amount of bone loss.
What is the current status of trial NCT04167163?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 58 participants. The study started on 2020-01-10. Estimated completion is 2025-04-03.
What conditions does trial NCT04167163 study?
This clinical trial studies the following conditions: Osteoporosis, Arthroplasties, Knee Replacement.
What interventions are being tested in trial NCT04167163?
The interventions under investigation include: Abaloparatide (DRUG).
Who is sponsoring clinical trial NCT04167163?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04167163 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preserving Geriatric Muscle With an Osteoporosis Medication
RECRUITING · Phase 4
-
Combined Anabolic Therapy
RECRUITING · Phase 4
-
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
ACTIVE NOT RECRUITING · Phase 4
-
Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study
ACTIVE NOT RECRUITING · Phase 4
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.